News
SLS
1.630
+5.84%
0.090
Weekly Report: what happened at SLS last week (0415-0419)?
Weekly Report · 2d ago
Sellas Life Sciences Group: A Lottery Ticket With An Estimated 9x Payout
Seeking Alpha · 4d ago
Weekly Report: what happened at SLS last week (0408-0412)?
Weekly Report · 04/15 09:59
Weekly Report: what happened at SLS last week (0401-0405)?
Weekly Report · 04/08 10:02
Weekly Report: what happened at SLS last week (0325-0329)?
Weekly Report · 04/01 10:01
SELLAS Life Sciences Gr Q4 EPS $(0.25) Misses $(0.21) Estimate
Benzinga · 03/29 03:35
SLS Stock Earnings: SELLAS Life Sciences Gr Misses EPS for Q4 2023
SELLAS Life Sciences Gr reported results for the fourth quarter of 2023. The company did not report any revenue for the quarter. SELLAS reported earnings per share of -25 cents. This was below the analyst estimate for EPS of -21 cents.
Investorplace · 03/29 02:54
SELLAS Life Sciences GAAP EPS of -$1.34 misses by $0.24
SELLAS Life Sciences GAAP EPS of -$1.34 misses by $0.24. As of December 31, 2023, cash and cash equivalents totaled approximately $2.5 million. The Company received gross proceeds of $9.0 million from a public offering in January 2024.
Seeking Alpha · 03/28 20:57
Sellas Life Sciences Group Files For Mixed Shelf Offering Of Up To $200M
Benzinga · 03/28 20:50
*SELLAS Life Sciences 2023 R&D Expenses $24M >SLS
Dow Jones · 03/28 20:11
*SELLAS Life Sciences 2023 Loss/Shr $1.34 >SLS
Dow Jones · 03/28 20:11
Press Release: SELLAS Life Sciences Reports Full -3-
The company reported total assets as of December 31, 2017. The company has a total of $20,000 million in cash and cash equivalents and $6.2 million in shareholders' equity. The number of shares outstanding is based on a weighted average share price of $1.75 per share. The company expects to be in the black by the end of 2017.
Dow Jones · 03/28 20:05
Buy Rating for SELLAS Life Sciences Amid Positive AML Study Results and Strengthened Financials
TipRanks · 03/27 18:25
SELLAS Announces Topline Data From Phase 2a Study of SLS009 In Relapsed/Refractory Acute Myeloid Leukemia And Provides Steering Committee Update on Phase 3 REGAL Study
Phase 2a study of SLS009 in r/r AML shows 50% response rate. First CR patient in the study continues to be leukemia-free 9 months after enrollment. Company is also conducting a Phase 3 study of GPS in AML. The company says the study is expected to be completed in April.
Benzinga · 03/26 11:37
SELLAS Announces Positive Topline Data from the Phase 2a Study of SLS009 in r/r AML and Provides Steering Committee Update on Phase 3 REGAL Study
- Phase 3 REGAL Study of GPS in AML: Enrollment Completed. 50% Response Rate in the Selected Optimal Dose of 30 mg BIW Exceeded the Targeted 20%. 100% Response rate in Patients with Identified Biomarkers to date.
Barchart · 03/26 06:35
Weekly Report: what happened at SLS last week (0318-0322)?
Weekly Report · 03/25 10:03
Catalyst Watch: Walgreens earnings, UPS analyst day and Xiaomi's luxury EV debut
Seeking Alpha's Catalyst Watch looks at next week's key events. Options trading volume is elevated on Digital World Acquisition (DWAC) ahead of the potential listing of Trump Media & Technology. The Nevada Gaming Control Board report for February will be released. United Parcel Service (UPS) will hold its Analyst Day.
Seeking Alpha · 03/22 19:00
Press Release: SELLAS Life Sciences Group Announces Closing of $20 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules
SELLAS Life Sciences Group Announces Closing of $20 million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules. SELLAS is a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications. The Company intends to use the net proceeds from the Offering for research and development.
Dow Jones · 03/19 20:05
SELLAS Life Sciences to Host Corporate Update Call on March 26, 2024, at 8:15 am ET
Barchart · 03/19 07:47
Weekly Report: what happened at SLS last week (0311-0315)?
Weekly Report · 03/18 10:02
More
Webull provides a variety of real-time SLS stock news. You can receive the latest news about Sellas Life Sciences Group Inc through multiple platforms. This information may help you make smarter investment decisions.
About SLS
SELLAS Life Sciences Group, Inc. is a late-stage clinical biopharmaceutical company. The Company is focused on the development of novel therapeutics for a range of cancer indications. The Company's product candidates, galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1 (WT1), antigen, and SLS009, a selective small molecule cyclin-dependent kinase 9 (CDK9), inhibitor. GPS is a cancer immunotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center (MSK), that targets the WT1 protein, which is present in an array of tumor types. GPS has potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic malignancies and solid tumor indications. The Company is developing SLS009, which is licensed from GenFleet Therapeutics (Shanghai), Inc., for all therapeutic and diagnostic uses in the world outside of Greater China.